Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 3.40 | — | — | 0.19 | — | — | — | — | — | — | 49.36 | — | — | — | — | — | — | — | 0.48 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.96 | — | — | 0.20 | — | — | — | — | — | — | — | — | 9.10 | 3.99 | 5.04 | 22.58 | 28.83 | 35.24 | 54.84 | 64.85 | 67.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | -68.4% | -88.7% | -90.8% | -65.2% | -57.0% | -24.9% | +1256.5% | -53.2% | -68.6% | |
| P/B Ratio | 2.41 | 2.45 | 1.95 | 1.04 | — | — | — | 6.59 | 29.45 | 6.41 | 4.17 | — | — | 0.43 | 0.39 | 0.41 | 0.44 | 0.47 | 0.66 | 1.23 | 2.26 |
| — | — | — | -84.2% | — | — | — | — | — | +1395.7% | +965.0% | — | — | -8.9% | -40.8% | -66.8% | -80.5% | -74.3% | -72.0% | -55.8% | -20.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | 1.06 | 5.29 | — | 1.90 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 4.17 | — | — | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 4.27 | — | — | 0.05 | — | — | — | -0.82 | — | — | — | — | — | — | — | — | — | — | -0.13 | — | — |
| — | — | — | +105.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | 100.0% | — | — | — | — | — | — | — | 100.0% | 93.3% | 96.1% | 95.7% | 21.1% | 20.8% | 2.0% | 32.0% | -198.6% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | +374.6% | +348.2% | +4718.6% | +198.6% | +110.6% | -79.2% | -98.0% | — | — | — | |
| Operating Margin | 31.5% | — | — | 85.4% | — | — | — | — | — | — | — | 176.0% | -419.5% | -227.0% | -250.2% | -4301.0% | -4097.5% | -3529.6% | -4690.5% | -4192.6% | -1828.3% |
| — | — | — | — | — | — | — | — | — | — | — | +104.1% | +89.8% | +93.6% | +94.7% | -2.6% | -124.1% | -152.7% | -123621.3% | -37.9% | +63.3% | |
| Net Margin | 55.5% | — | — | 107.4% | — | — | — | — | — | — | — | 184.6% | -754.8% | -181.2% | -232.0% | -4276.2% | -4205.2% | -3627.1% | 11484.4% | -4187.4% | -1825.2% |
| — | — | — | — | — | — | — | — | — | — | — | +104.3% | +82.1% | +95.0% | -102.0% | -2.1% | -130.4% | -160.1% | +313753.3% | -37.7% | +63.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 125.1% | -11.8% | -17.2% | 489.9% | — | — | -1328.2% | -118.4% | -67.9% | -41.3% | 2.1% | — | — | -4.3% | -4.1% | -17.7% | -15.0% | -11.5% | 42.3% | -18.2% | -14.5% |
| — | — | +98.7% | +513.8% | — | — | -63052.6% | — | — | -863.9% | +150.9% | — | — | +62.7% | -109.8% | +2.8% | -3.8% | +19.9% | +7914.2% | -12.1% | +6.5% | |
| ROA | 38.7% | -10.0% | -12.1% | 96.6% | -11.9% | -13.1% | -12.9% | -14.4% | -15.4% | -12.3% | 1.0% | -53.7% | -12.6% | -3.2% | -3.2% | -14.0% | -12.3% | -9.8% | 35.2% | -15.2% | -12.5% |
| — | +23.8% | +5.8% | +770.0% | +22.5% | -6.5% | -1347.1% | +73.2% | -22.3% | -288.2% | +132.2% | -284.4% | -2.0% | +67.6% | -109.1% | +8.0% | +1.4% | +21.0% | +8286.6% | -25.4% | -7.7% | |
| ROIC | — | -102.0% | -63.4% | — | — | — | — | — | — | — | — | — | — | -5.1% | -3.5% | -14.0% | -17.4% | -32.6% | -44.3% | -25.0% | -19.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +84.3% | +92.1% | +44.0% | +9.8% | -66.3% | -2699.0% | +98.7% | +76.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.04 | 0.29 | 0.37 | — | — | — | 3.33 | 1.06 | 0.59 | 0.41 | — | — | 0.24 | 0.19 | 0.17 | 0.14 | 0.10 | 0.09 | 0.14 | 0.07 |
| — | — | — | -89.0% | — | — | — | — | — | +146.2% | +115.6% | — | — | +140.9% | +112.7% | +17.4% | +109.2% | +58.1% | +22.1% | +79.1% | -27.6% | |
| Debt / EBITDA | 0.89 | — | — | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.85 | 20.30 | 5.33 | 4.85 | 4.57 | 5.06 | 4.71 | 4.97 | 6.53 | 6.49 | 4.19 | 2.04 | 0.54 | 5.73 | 8.30 | 8.02 | 8.44 | 11.50 | 12.62 | 11.14 | 10.25 |
| — | +301.5% | +13.2% | -2.4% | -29.9% | -22.1% | +12.4% | +144.3% | +1099.4% | +13.4% | -49.5% | -74.6% | -93.6% | -50.2% | -34.2% | -28.0% | -17.7% | +3.1% | +17.2% | +15.0% | -2.8% | |
| Quick Ratio | 4.85 | 20.30 | 5.33 | 4.85 | 4.57 | 5.06 | 4.71 | 4.97 | 6.53 | 6.49 | 4.19 | 2.04 | 0.52 | 5.73 | 8.30 | 8.07 | 8.44 | 11.50 | 12.62 | 11.14 | 10.25 |
| — | +301.5% | +13.2% | -2.4% | -29.9% | -22.1% | +12.4% | +144.3% | +1166.3% | +13.4% | -49.5% | -74.8% | -93.9% | -50.2% | -34.2% | -27.6% | -17.7% | +3.1% | +17.2% | +15.0% | -2.8% | |
| Interest Coverage | 28.11 | — | — | 289.65 | -23.63 | -30.63 | -40.76 | — | -57.65 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QTTB stock.
Q32 Bio Inc.'s current P/E is 3.4x. The average P/E over the last 1 quarters is 0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Q32 Bio Inc.'s current operating margin is 31.5%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Q32 Bio Inc.'s business trajectory between earnings reports.